Kun for helsepersonell
How can we improve outcomes for patients with R/R LBCL?
Interview: 6 minutes
Listen to Professor Mats Jerkeman from Skåne University Hospital in Lund, Sweden, as he discusses the treatment gap in R/R LBCL, which patients are suitable for CAR-T, the expected benefits, and the side effect profile associated with CAR-T therapy.
References:
- Breyanzi Product resumé, European Medicines Agency
- Yescarta Product resumé, European Medicines Agency
Related videos
Breyanzi®- From Mode of Action to administration
Expanding the CAR T Portfolio
News
Learn about current topics in hematology, such as new research data, news from events, congresses and more.
Education
Find past and upcoming educational events and access learning tools such as webinars, training videos and expert interviews.
HE-DK-2500006 Oct 2025 video /2009-NO-2500020 Dec 2025